
In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
| Revenue (TTM) | $9.53B |
| Gross Profit (TTM) | $6.83B |
| EBITDA | $4.07B |
| Operating Margin | 40.70% |
| Return on Equity | 64.90% |
| Return on Assets | 15.30% |
| Revenue/Share (TTM) | $22.14 |
| Book Value | $7.84 |
| Price-to-Book | 9.40 |
| Price-to-Sales (TTM) | 3.08 |
| EV/Revenue | 3.901 |
| EV/EBITDA | 9.25 |
| Quarterly Earnings Growth (YoY) | 1.20% |
| Quarterly Revenue Growth (YoY) | -0.20% |
| Shares Outstanding | $413.22M |
| Float | $412.37M |
| % Insiders | 0.16% |
| % Institutions | 99.99% |
Volatility is currently contracting

In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://in.

Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but international and livestock segments showed resilience and growth. Management revised 2026 guidance downward, but ZTS's low valuation multiples and aggressive share buybacks support its fair value case.

Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides.

Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.

Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Michael Burry, a hedge fund manager and investor known for predicting the 2008 financial crash, has just updated his portfolio, with some notable new positions catching the market's attention.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be ava.

Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.

Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZTS and any ticker you trade — then tracks every position and per-strategy win rate.